Document Detail

Evaluation of isradipine and captopril alone or in combination for the treatment of hypertension.
MedLine Citation:
PMID:  1720478     Owner:  NLM     Status:  MEDLINE    
The antihypertensive effects of isradipine and captopril were studied in 231 patients with mild-to-moderate hypertension in a double-blind, randomized, between-patient trial. Treatment was started with 1.25 mg of isradipine or 12.5 mg of captopril twice daily which, if normotension was not obtained, was increased after 4 weeks to 2.5 mg or 25 mg twice daily, respectively. If the maximum dose of each drug alone did not result in normotension, captopril (12.5 mg or, if necessary, 25 mg twice daily) was added to the isradipine regimen, and isradipine (1.25 mg or, if necessary, 2.5 mg twice daily) to the captopril regimen. Following 24 weeks of active treatment, systolic blood pressure (SBP) was significantly (p less than 0.001) reduced by isradipine (170 +/- 17 vs. 153 +/- 17 mm Hg) and by captopril (170 +/- 19 vs. 155 +/- 19 mm Hg). Diastolic blood pressure (DBP) also fell significantly (p less than 0.001) in both groups (isradipine: 106 +/- 5 vs. 93 +/- 8 mm Hg; captopril: 106 +/- 5 vs. 95 +/- 10 mm Hg). After isradipine as monotherapy, DBP was normalized in 49% of patients compared with 52% after captopril monotherapy. Combination of both drugs increased the normalization rate to 84%. The results indicate that combined treatment with a calcium antagonist and an angiotensin-converting enzyme (ACE) inhibitor is effective in lowering blood pressure, and is well tolerated as long-term therapy.
P Fitscha; W Meisner; G Hitzenberger
Related Documents :
8088918 - Effect of captopril and enalapril on endothelial function in hypertensive patients.
11170618 - Hypotensive and physiological effect of angiotensin converting enzyme inhibitory peptid...
3944048 - Heat acclimation: cardiac performance of isolated rat heart.
7022748 - The effect of captopril on heart rate in several types of hypertensive patients.
3723308 - An antireflux procedure for use with the reversed gastric tube.
12122498 - Local administration of eta (but not etb) blockers into the pag area of the brain decre...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  18 Suppl 3     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1991  
Date Detail:
Created Date:  1992-01-09     Completed Date:  1992-01-09     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S12-4     Citation Subset:  IM    
Department of Internal Medicine II, Vienna Polyclinic, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antihypertensive Agents / adverse effects,  therapeutic use*
Blood Pressure / drug effects
Calcium Channel Blockers / adverse effects,  therapeutic use*
Captopril / adverse effects,  therapeutic use*
Dihydropyridines / adverse effects,  therapeutic use*
Double-Blind Method
Drug Therapy, Combination
Heart Rate / drug effects
Hypertension / drug therapy*
Middle Aged
Reg. No./Substance:
0/Antihypertensive Agents; 0/Calcium Channel Blockers; 0/Dihydropyridines; 62571-86-2/Captopril; 75695-93-1/Isradipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Calcium antagonists as first-line therapy in hypertension: results of the Swiss Isradipine Study. Sw...
Next Document:  The Multicenter Isradipine/Diuretic Atherosclerosis Study: a study of the antiatherogenic properties...